To evaluate the therapeutic potential of the identified DHHC9 inhibitors in vivo, we treated mice bearing CT‐26 colon cancer cells in the spontaneous spleen‐to‐liver metastasis model with Treprostinil (100 μg/kg) or 10‐HCPT (2 mg/kg) via intraperitoneal injection, alongside a vehicle control group (Figure 7A–G). This evidence concerns the gene ZDHHC9 and colonic neoplasm.